Genital Herpes - Pipeline Insight, 2022

Genital Herpes - Pipeline Insight, 2022

DelveInsight’s, “Genital Herpes - Pipeline Insight, 2022,” report provides comprehensive insights about 26+ companies and 28+ pipeline drugs in Genital Herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Genital Herpes Understanding

Genital Herpes: Overview

Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors 1. Due to marked genetic homology between HSV-1 and HSV-2 numerous biological similarities and antigenic cross-reactions between the viruses exist. Type-specific epitopes include the viral glycoproteins (g) gG (HSV-1 and HSV-2) and gC (HSV-1). The primary mode of transmission of both HSV-1 and HSV-2 is through direct contact. Initial infection with HSV-1 occurs most often during childhood following the disappearance of maternal antibodies during the first year of life.

""Genital Herpes - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Genital Herpes pipeline landscape is provided which includes the disease overview and Genital Herpes treatment guidelines. The assessment part of the report embraces, in depth Genital Herpes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
 
Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence in Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve in Genital Herpes.

This segment of the Genital Herpes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Genital Herpes Emerging Drugs

Pritelivir: AiCuris

Pritelivir is a highly potent inhibitor of HSV replication. It belongs to a new chemical class and acts via a novel mechanism of action (inhibition of the viral helicase-primase enzyme complex). In contrast to currently used nucleoside analogues, Pritelivir does not require activation by viral enzymes and can thus protect uninfected cells. Pritelivir is being developed for the treatment of acyclovir-resistant and dual-resistant (resistant to acyclovir and intolerant or resistant to foscarnet) infections in immune-compromised patients.

UB 621: United BioPharma

UB 621 is a novel, fully human monoclonal antibody that interferes with HSV infection by binding specifically to HSV envelope glycoprotein D (gD). It has been shown in vitro to block HSV infections of both wild type and acyclovir-resistant viral strains with over hundreds-fold higher potency. Pre-clinical and early clinical data show that UB-621 has the potential to suppress recurrence of genital herpes. The drug is in phase II stage of development for the treatment of Genital Herpes.

Further product details are provided in the report……..

Genital Herpes: Therapeutic Assessment

This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Genital Herpes

There are approx. 26+ key companies which are developing the therapies for Genital Herpes. The companies which have their Genital Herpes drug candidates in the most advanced stage, i.e. Phase III include, AiCuris.

Phases

DelveInsight’s report covers around 28+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Genital Herpes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Genital Herpes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Genital Herpes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Herpes drugs.

Genital Herpes Report Insights

Genital Herpes Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Genital Herpes Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs
 
Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Genital Herpes drugs?

How many Genital Herpes drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital Herpes?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Genital Herpes?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Genital Herpes and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AiCuris

United BioPharma

Heidelberg ImmunoTherapeutics

Immune System Regulation

Admedus Immunotherapies

Brandenburg Antiinfektiva GmbH

Starpharma

BioNTech

GlaxoSmithKline

Auritec Pharmaceuticals

JN-International Medical Corporation

BlueWillow Biologics

Moderna Therapeutics

Assembly Biosciences

Shulov Institute for Science LTD

X-Vax Technology

Vaxxit

Nanoviricides

Key Products

Pritelivir

UB 621

HDIT 101

ISR048

HSV-2 DNA Vaccine

Aspidasept

VivaGel

BNT 163

GSK 3943104A

Aciclovir Intravaginal Ring

Genital herpes Vaccine

NE HSV-2 vaccine

mRNA 1608

HSV-2 Long-Acting Helicase Inhibitor

ZEP-3

delta gD-2

Attenuated vaccine against HSV 1&2

HSV “Genital lesions” Skin cream/Lotion